Overview
COMPASS Pathways is a mental health care company focused on accelerating patient access to psilocybin therapy, with their proprietary COMP360 psilocybin formulation in Phase 3 trials for treatment-resistant depression. They are one of the most advanced and well-funded psychedelic medicine companies globally.
More in Psychedelics
Latest industry news
It's Finally Here: FacialDx, an AI-Powered Support Tool for Sideline Concussion Assessments
2026-06-23 · Product
MIT Researchers Demonstrate Real-Time Emotion Decoding via Non-Invasive EEG with 94% Accuracy
2026-06-13 · Research
Synchron Launches Stentrode Home Edition, Expanding BCI Access Beyond Clinical Settings
2026-06-11 · Product
Synchron Reaches 100-Patient Milestone as Stentrode BCI Moves Toward Pivotal Trial
2026-06-09 · Industry
Company details
Category
🍄 Psychedelics
Location
London, UK
Funding
NASDAQ: CMPS · $280M+
Website
compasspathways.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →